John Henry Kenten from 21021 Sugar Ridge Ter, Boyds, MD 20841, age 68, Phone: 3019166171

Name / Title

Company / Classification

Phones & Addresses

John Kenten
Scientific Director

Meso Scale Diagnostics, LLC

9238 Gaither Rd, Gaithersburg, MD 20877
2406312522

Controlling Protein Levels In Eucaryotic Organisms
view source
US Patent:

6559280, May 6, 2003
Filed:

Jun 14, 2001
Appl. No.:

09/880132
Inventors:

John H. Kenten - Boyds MD
Steven F. Roberts - Bethesda MD
Assignee:

Proteinix, Inc. - Gaithersburg MD
International Classification:

A61K 3800
US Classification:

530323, 424 7014, 435 4, 435106, 435108, 435109, 435115, 435116, 436501, 514 2, 530329, 530330, 530331, 530332
Abstract:

The invention relates to novel compounds comprising a ubiquitination recognition element and a protein binding element. The invention also relates to the use of said compounds for modulating the level and/or activity of a target protein. The compounds are useful for the treatment of disease such as infections, inflammatory conditions, cancer and genetic diseases. The compounds are also useful as insecticides and herbicides.

Ubiquitin Fusion-Based Vaccine System
view source
US Patent:

6660271, Dec 9, 2003
Filed:

Sep 26, 2001
Appl. No.:

09/964201
Inventors:

John H. Kenten - Boyds MD
Alfonso Tramontano - Rockville MD
Aprile L. Pilon - Gaithersburg MD
Gerald L. Lohnas - Catonsville MD
Steven F. Roberts - Bethesda MD
Assignee:

Proteinix Company - Gaithersburg MD
International Classification:

A61K 39385
US Classification:

4241921, 424184, 42419511, 530399, 530402, 530403, 514 8, 514 12
Abstract:

Disclosed are epitope-containing heat shock fusion proteins, DNA constructs encoding such fusion proteins, and methods of use. More specifically, disclosed are ubiquitin fusion proteins comprising ubiquitin fused to a plurality of identical or non-identical epitopes at specified locations.

Prodrugs Activated By Targeted Catalytic Proteins
view source
US Patent:

6702705, Mar 9, 2004
Filed:

Feb 22, 1995
Appl. No.:

08/392407
Inventors:

Reid von Borstel - Potomac MD
Jan M. Casadei - Bethesda MD
Balreddy Kamireddy - Rockville MD
John Kenten - Gaithersburg MD
Mark T. Martin - Germantown MD
Richard J. Massey - Rockville MD
Andrew D. Napper - Natick MA
David M. Simpson - Adelphia MD
Rodger Smith - Jefferson MD
Richard C. Titmas - Rockville MD
Richard O. Williams - Potomac MD
Assignee:

IGEN International, Inc. - Gaithersburg MD
International Classification:

C12N 900
US Classification:

4751885
Abstract:

Catalytic antibodies are disclosed. The catalytic antibodies are specific for prodrug compounds. The catalytic antibodies enhance cleavage of an active drug moiety from a prodrug residue, thereby activating the drug.

Electrochemiluminescent Localizable Complexes For Assay Compositions
view source
US Patent:

6881589, Apr 19, 2005
Filed:

Jun 5, 1995
Appl. No.:

08/465443
Inventors:

John K. Leland - Laurel MD, US
Haresh P. Shah - Gaithersburg MD, US
John H. Kenten - Gaithersburg MD, US
Jack E. Goodman - Arlington VA, US
George E. Lowke - Laytonsville MD, US
Yuzaburo Namba - Tsukuba, JP
Gary F. Blackburn - Gaithersburg MD, US
Richard J. Massey - Rockville MD, US
Assignee:

BioVeris Corporation - Gaithersburg MD
International Classification:

G01N033/53
G01N033/544
G01N033/566
G01N021/00
US Classification:

436501, 436518, 436508, 436531, 436544, 436149, 436164, 436172, 436805, 436806, 435 71
Abstract:

The invention provides compositions and kits for performing a binding assay for an analyte of interest present in a sample based upon electrochemiluminescence. The compositions and kits comprise an electrochemiluminescent label, collectable particles, binding reagents, and an electrolyte.

Cycling Dna/Rna Amplification Electrochemiluminescent Probe Assay
view source
US Patent:

6890712, May 10, 2005
Filed:

Jan 10, 2000
Appl. No.:

09/480544
Inventors:

John H. Kenten - Gaithersburg MD, US
Rodger Smith - Jefferson MD, US
Assignee:

BioVeris Corporation - Gaithersburg MD
International Classification:

C12Q001/68
C12P019/34
US Classification:

435 6, 435 911, 435 912, 435 9121, 435 915, 435 9151
Abstract:

This invention relates to an improved process for detecting and quantifying a desired nucleic acid sequence. The process involves synthesizing single stranded RNA, single stranded DNA, double-stranded DNA followed by detection using an electrochemiluminescent labeled binding species.

Methods, Reagents, Kits And Apparatus For Protein Function Analysis
view source
US Patent:

7063946, Jun 20, 2006
Filed:

Sep 10, 2002
Appl. No.:

10/238960
Inventors:

John H. Kenten - Boyds MD, US
Hans Biebuyck - Rockville MD, US
Ilia Davydov - North Potomac MD, US
Nisar Pampori - Frederick MD, US
Steven Yan Cheng - Rockville MD, US
Stefanie Nelson - Silver Spring MD, US
Assignee:

Meso Scale Technologies, LLC. - Gaithersburg MD
International Classification:

C12Q 1/68
US Classification:

435 6
Abstract:

Apparatus, systems, system components, methods, compositions, and reagents for determining the function and activity of peptides and proteins and for identifying and characterizing molecules that affect these functions and activities. More specifically, methods and reagents used to determine the various activities of peptides and proteins including their binding specificity, binding activity, their enzymatic activity and their ability to act as substrates for enzymes. The disclosed methods are especially suited for the analysis of peptide and protein function where large numbers of peptides and proteins need to be analyzed.

Controlling Protein Levels In Eucaryotic Organisms
view source
US Patent:

7074620, Jul 11, 2006
Filed:

Jun 14, 2001
Appl. No.:

09/880149
Inventors:

John H. Kenten - Boyds MD, US
Steven F. Roberts - Bethesda MD, US
Assignee:

Proteinix, Inc. - Gaithersburg MD
International Classification:

G01N 33/566
US Classification:

436501, 424 91, 424 92, 4241341, 4241361, 4241851, 435 4, 435 71, 530300, 530323, 530332, 530344
Abstract:

Method for reducing the level and/or activity of a target protein in a eukaryotic cell via activation of ubiquitination of the target protein wherein the cell is contacted with the compound having a ubiquitination recognition element covalently linked to a target protein binding element. The ubiquitination and recognition element can bind to either the E3 or E2 elements of the ubiquitination system and the target protein binding element is able to bind specifically to the target protein. The target protein binding element has a molecular weight of less than 30,000 and has a binding affinity for the target protein greater than 10M.

Controlling Protein Levels In Eucaryotic Organisms
view source
US Patent:

7273920, Sep 25, 2007
Filed:

Jan 16, 2003
Appl. No.:

10/345281
Inventors:

John H. Kenten - Boyds MD, US
Steven F. Roberts - Bethesda MD, US
Assignee:

Wellstat BioCatalysis, LLC - Gaithersburg MD
International Classification:

A61K 38/00
C12P 21/04
C12P 13/10
C12P 13/06
G01N 33/53
US Classification:

530323, 435 701, 435 71, 435113, 435114, 435116
Abstract:

The invention relates to novel compounds comprising a ubiquitination recognition element and a protein binding element. The invention also relates to the use of said compounds for modulating the level and/or activity of a target protein. The compounds are useful for the treatment of disease such as infections, inflammatory conditions, cancer and genetic diseases. The compounds are also useful as insecticides and herbicides.